The challenges of gout flare reporting: mapping flares during a randomized controlled trial

BMC Rheumatology

Table 2 Spearman correlations between methods of reporting flares and other measures of disease activity. ^aadjusted for duration of follow-up for each participant. The area under the curve (AUC) for the measures of gout flare activity over the observation period was used in this analysis

		Self-reported flare				Gaffo CART-defined flare				AUC pain-by-time plot
		Time to first flare^a	Number of flares	Number of months with ≥ 1 flare	Days with flare	Time to first flare^a	Number of flares	Number of months with ≥ 1 flare	Days with flare	AUC pain-by-time plot
Swollen joint count	r	−0.07	0.31	0.36	0.51	−0.20	0.37	0.42	0.41	0.50
Swollen joint count	P	0.49	0.001	< 0.001	< 0.001	0.04	< 0.001	< 0.001	< 0.001	< 0.001
Tender joint count	r	−0.18	0.34	0.35	0.49	−0.20	0.29	0.35	0.33	0.44
Tender joint count	P	0.07	< 0.001	< 0.001	< 0.001	0.04	0.002	< 0.001	< 0.001	< 0.001
C-reactive protein	r	0.00	0.10	0.21	0.30	−0.31	0.24	0.28	0.32	0.34
C-reactive protein	P	0.99	0.30	0.03	0.002	0.001	0.01	0.003	0.001	0.001
Patient global assessment	r	−0.19	0.44	0.45	0.62	−0.35	0.54	0.60	0.61	0.67
Patient global assessment	P	0.04	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001
Physician global assessment	r	−0.20	0.44	0.45	0.62	−0.35	0.54	0.60	0.60	0.67
Physician global assessment	P	0.04	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001

ISSN: 2520-1026